Novel therapies for diabetic retinopathy

Magdalena Kupis; Katarzyna Samelska; Jacek Szaflik; Piotr Skopiński

doi:10.5114/ceji.2022.112993

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

1/2022
vol. 47

Send email

Copy url:

abstract:

Review paper

Novel therapies for diabetic retinopathy

Magdalena Kupis

¹

,

Katarzyna Samelska

¹

,

Jacek Szaflik

¹

,

Piotr Skopiński

²

Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland
Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland

Cent Eur J Immunol 2022; 47 (1): 102-108

DOI: https://doi.org/10.5114/ceji.2022.112993

Online publish date: 2022/01/28

View full text Get citation

PlumX metrics:

Diabetes mellitus (DM) is a metabolic disease characterized by high blood glucose levels as well as microvascular and macrovascular changes. According to the latest statistics the growth of DM incidence is very fast. Diabetic retinopathy (DR) – one of the common DM complications – is the leading cause of blindness among professionally active people. Traditional treatment of DR including drugs controlling hyperglycemia, laser therapy, vitrectomy, and intravitreal injections of anti-VEGF is effectively administered with the effect of neovascularization and macular edema prevention. However, new potential DR therapies – focusing on a longer therapeutic effect and potentially fewer side effects – are being widely investigated. Gene therapy – targeting retinal vasculopathy or targeting retinal protection, mesenchymal stem cell injections, SGLT2 inhibitors, and islet cell transplantation have been proved to stop DR progression. The majority of the new treatment research was performed on an animal model and did not reach the final study stage. A further future human model and randomized studies with optimized delivery vectors will hopefully confirm positive outcomes of the new DR therapies.

keywords:

Novel therapies for diabetic retinopathy

Magdalena Kupis 1 , Katarzyna Samelska 1 , Jacek Szaflik 1 , Piotr Skopiński 2

diabetic retinopathy, gene therapy, mesenchymal stem cells, SGLT2 inhibitors, islet cell transplantation

Magdalena Kupis

¹

,

Katarzyna Samelska

¹

,

Jacek Szaflik

¹

,

Piotr Skopiński

²